High Gross MarginsA consistent gross profit margin above 75% indicates durable product-level economics and pricing power. Such structural margin strength provides a clear path to scalable profitability if operating expenses are controlled, supporting long-term gross cash generation potential even while current operating losses persist.

Improving Leverage MetricsMeasured improvement in debt-to-equity signals improved leverage management and lower near-term refinancing pressure. Better capital structure enhances financial flexibility to fund R&D or commercial initiatives and reduces interest burden risk, strengthening balance sheet resilience over the coming months.

Board-backed Going-private ProposalA board- and special-committee-backed plan to go private is a structural strategic change that can enable longer-term restructuring, reduce public reporting costs, and align management with owners. If completed, it can allow multi-year operational fixes without quarterly market pressures, supporting durable strategic execution.

Bears Say

Persistent Operating LossesOngoing negative EBIT and free cash flow erode liquidity and require external financing or asset sales to sustain operations. This structural cash-burn constrains strategic choices, increases dependency on capital markets or lenders, and heightens execution risk for commercialization over the next several months.

Material Arbitration Awards & Fraud ProbeLarge disputed arbitration liabilities combined with an active fraud probe create material contingent obligations and severe governance risk. Possible cash outflows, penalties, or reputational harm could impair partnerships, limit financing access, and materially alter the company’s strategic and financial plans over the medium term.

Merger Completion UncertaintyThe buyer group's challenge and EGM postponement introduce structural uncertainty around the going-private transaction. Delay or renegotiation can affect governance, liquidity planning, and strategic execution, prolonging public-market distractions and leaving the company without the anticipated private capital and operational flexibility.

LakeShore Biopharma News

LakeShore Biopharma’s Buyer Group Challenges Merger After RMB576.5 Million Arbitral Hit, Forcing EGM Delay

LakeShore Biopharma ( ($LSBCF) ) has shared an update. On February 6, 2026, LakeShore Biopharma disclosed that the...

1M ago

LakeShore Biopharma Faces Disputed RMB500 Million Arbitration Awards Amid Fraud Investigation

LakeShore Biopharma ( ($LSBCF) ) just unveiled an update. On January 21 and 22, 2026, LakeShore Biopharma reported...

2M ago

LakeShore Biopharma Sets February 12 EGM to Approve Going-Private Merger

An announcement from LakeShore Biopharma ( ($LSBCF) ) is now available. On January 20, 2026, LakeShore Biopharma announced...

2M ago

LakeShore Biopharma Announces Going-Private Transaction Agreement

LakeShore Biopharma ( ($LSBCF) ) just unveiled an update. On November 4, 2025, LakeShore Biopharma announced a definitive...

5M ago

LSBCF FAQ

What was LakeShore Biopharma’s price range in the past 12 months?

LakeShore Biopharma lowest stock price was $0.04 and its highest was $2.80 in the past 12 months.

What is LakeShore Biopharma’s market cap?

LakeShore Biopharma’s market cap is $1.65M.

When is LakeShore Biopharma’s upcoming earnings report date?

LakeShore Biopharma’s upcoming earnings report date is Apr 17, 2026 which is in 26 days.

How were LakeShore Biopharma’s earnings last quarter?

Currently, no data Available

Is LakeShore Biopharma overvalued?

According to Wall Street analysts LakeShore Biopharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does LakeShore Biopharma pay dividends?

LakeShore Biopharma does not currently pay dividends.

What is LakeShore Biopharma’s EPS estimate?

LakeShore Biopharma’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does LakeShore Biopharma have?

LakeShore Biopharma has 41,212,692 shares outstanding.

What happened to LakeShore Biopharma’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of LakeShore Biopharma?

Currently, no hedge funds are holding shares in LSBCF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

LakeShore Biopharma

LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 2002 and is based in Beijing, China.